Welcome to our dedicated page for DECOY THERAPEUTICS SEC filings (Ticker: DCOY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoy Therapeutics Inc. filings document the company's public-company governance, capital structure, and corporate-status records following its name change from Salarius Pharmaceuticals, Inc. to Decoy Therapeutics Inc. The filing record includes Form 8-K reports on certificate and bylaw amendments, the DCOY trading symbol, Nasdaq Capital Market listing matters, and amendments affecting common stock.
Proxy and meeting disclosures cover shareholder voting matters, including approval of an equity incentive plan and authorization for a reverse stock split. Additional filings describe the completed 1-for-12 reverse stock split, related security-holder rights changes, Nasdaq minimum bid price compliance, governance procedures, operating and financial results, and other material-event reporting for the issuer.
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, is asking stockholders at a virtual special meeting on February 24, 2026 to approve a new 2026 Equity Incentive Plan and a reverse stock split.
The 2026 plan would authorize 1,100,000 shares initially, with automatic annual increases of 6% of shares outstanding on December 31, 2026 and 5% each January 1 from 2028 through 2036 unless the board reduces or cancels an increase. As of December 26, 2025, ten employees and six non-employee directors would be eligible and the stock closed at $0.6573 per share.
The reverse split would combine shares at a ratio between 1‑for‑4 and 1‑for‑15, leaving 100,000,000 authorized shares but reducing the 6,384,177 shares outstanding (for example to 1,596,044 at 1‑for‑4). The board’s goal is to raise the share price to meet Nasdaq’s initial listing standards after a merger with Decoy, following a Nasdaq notice that the stock has traded below the $1.00 minimum bid and a pending delisting appeal.
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is changing its corporate identity. The company filed a Certificate of Amendment in Delaware to change its legal name to Decoy Therapeutics Inc., effective January 8, 2026, a step that did not require a stockholder vote and does not alter stockholder rights.
In connection with the name change, the board approved Second Amended and Restated Bylaws reflecting the new name. The company also announced that its common stock, previously trading under the symbol “SLRX”, is expected to begin trading on the Nasdaq Capital Market under the new ticker “DCOY” on January 8, 2026. A new corporate website at decoytx.com, including investor relations information and links to SEC filings, is being launched as part of this rebranding.